Skip to main content
SpringerLink
Log in

Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: preclinical and clinical efficacy

  • Review
  • Published:
Pharmacological Reports Aims and scope Submit manuscript

Abstract

Several clinical reports have documented a beneficial effect of adding atypical antipsychotic drugs to ongoing treatments with antidepressants, particularly selective serotonin reuptake inhibitors, in ameliorating drug-resistant depression. The aim of this paper was to summarize some preclinical evidence describing the mechanism responsible for the therapeutic action of combined treatment with antidepressants and atypical antipsychotics and also some clinical data supporting the efficacy and safety of the augmentation strategy for improving antidepressant-resistant depression using atypical antipsychotics. This analysis is based on five microdialysis studies and nine behavioral studies assessing the impact of combined atypical antipsychotic and antidepressant treatments on extracellular levels of dopamine, serotonin and noradrenaline in the prefrontal cortex of freely moving rats and on antidepressant-induced effects, respectively. In addition, clinical data demonstrating the efficacy and safety of augmentation strategies for treatmentresistant depression using atypical antipsychotics were included. Combined treatment of rats with all studied atypical antipsychotics (olanzapine, risperidone, clozapine and quetiapine) and antidepressants (citalopram, fluoxetine and fluvoxamine) increased the extracellular level of dopamine in the prefrontal cortex compared to a respective drug given alone; in addition, a combination of olanzapine or quetiapine plus fluoxetine or fluvoxamine increased the levels of dopamine and noradrenaline. Moreover, atypical antipsychotics administered in a low dose enhanced the antidepressant-like activity of antidepressants, with (among other mechanisms) the serotonin 5-HT1A, 5-HT2A and adrenergic a 2 receptors likely playing an important role in their action. The results support the conclusion that atypical antipsychotics may be effective as adjunctive therapy in treatment-resistant depression; however, their adverse effect profile may be unfavorable in some patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alexopoulos GS, Cansuso CM, Gharabawi GM, Bossie CA, Greenspan A, Turkoz I, Reynolds III C: Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry, 2008, 16, 21–30.

    Article  PubMed  Google Scholar 

  2. Amsterdam JD, Hornig-Rohan M: Treatment algorithms in treatment-resistant depression. Psychiatry Clin North Am, 1996, 19, 371–386.

    Article  CAS  Google Scholar 

  3. Bauer M, El-Khalili N, Datto C, Szamosi J, Eriksson H: A pooled analysis of two randomized, placebo-controlled studies, of extended release quetiapine fumarate to anti-depressant therapy in patients with major depressive disorder. J Affect Disord, 2010, 127, 19–30.

    Article  CAS  PubMed  Google Scholar 

  4. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M: Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry, 2009, 70, 540–549.

    Article  CAS  PubMed  Google Scholar 

  5. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH et al.: Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS, 2009, 14, 197–206.

    Google Scholar 

  6. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry, 2007, 68, 843–853.

    Article  CAS  PubMed  Google Scholar 

  7. Bourin M, Chenu F, Prica C, Hascoët M: Augmentation effect of combination therapy of aripiprazole and antide-pressants on forced swimming test in mice. Psychophar-macology, 2009, 206, 97–107.

    Article  CAS  PubMed  Google Scholar 

  8. Burda K, Czubak A, Kuś K, Nowakowska E, Ratajczak P, Zin J: Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats. Pharmacol Rep, 2011, 63, 898–907.

    CAS  PubMed  Google Scholar 

  9. Carroll BJ: Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology, 2008, 33, 2546–2547.

    Article  CAS  PubMed  Google Scholar 

  10. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G: A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety, 2006, 23, 364–372.

    Article  CAS  PubMed  Google Scholar 

  11. Denys D, Klompmakers AA, Westenberg HGM: Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psycho-pharmacology, 2004, 176, 195–203.

    Article  CAS  PubMed  Google Scholar 

  12. Dhir A, Kulkarni SK: Risperidone, an atypical antipsy-chotic enhances the antidepressant-like effect of venla-faxine or fluoxetine: Possible involvement of alpha-2 adrenergic receptors. Neurosci Lett, 2008, 445, 83–88.

    Article  CAS  PubMed  Google Scholar 

  13. El-Khalili N, Joyce M, Atkinson S, Buynaki RJ, Datto C, Lindgren P, Eriksson H: Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol, 2010, 13, 917–932.

    Article  CAS  PubMed  Google Scholar 

  14. Huang M, Ichiwara J, Li Z, Dai J, Meltzer HY: Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex. Psychopharmacology, 2006, 185, 274–281.

    Article  CAS  PubMed  Google Scholar 

  15. Ichikawa J, Kuroki T, Dai J, Meltzer HY: Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur J Pharmacol, 1998, 351, 163–171.

    Article  CAS  PubMed  Google Scholar 

  16. Jordan S, Koprivica V, ChenR, Tottori K, Kikuchi T, Altar A: The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol, 2002, 441, 137–140.

    Article  CAS  PubMed  Google Scholar 

  17. Kamei J, Miyata S, Sunohara T, Kamei A, Shimada M, Ohsawa M: Potentiation of the antidepressant-like effect of fluoxetine by aripiprazole in mice tail suspension test. J Pharmacol Sci, 2008, 108, 381–384.

    Article  CAS  PubMed  Google Scholar 

  18. Kamińska K, Gołembiowska K, Rogóż Z: The effect of risperidone on the fluoxetine-induced changes in extracellular dopamine, serotonin and noradrenaline in the rat frontal cortex. Pharmacol Rep, 2013, 65, 1144–1151.

    Article  PubMed  Google Scholar 

  19. Kato M, Chang C-M: Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression. CNS Drugs, 2013, 27, Suppl 1, S11–S19.

    Article  PubMed  Google Scholar 

  20. Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, Keller MB: A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatry Res, 2009, 43, 205–214.

    Article  Google Scholar 

  21. Kikuchi T, Tottori K, UwahodoY, Hirose T, Miwa T, Oshiro Y, Morita S: 7-(4-[4-(2,3-Dichlorophenyl)-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther, 1995, 274, 329–336.

    CAS  PubMed  Google Scholar 

  22. Maes M, Meltzer HY: The serotonin hypothesis of major depression. In: Psychopharmacology: The Fourth Generation of Progress. Eds. Bloom FE, Kupfer DJ, Raven Press Ltd., New York, 1995, 933–944.

    Google Scholar 

  23. Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, Gharabawi-Garibaldi GM: Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med, 2007, 147, 592–602.

    Article  Google Scholar 

  24. Marcus MM, Jardemark K, Malmerfelt A, Gertow J, Konradsson-Geuken Ä, Svensson TH: Augmentation of escitalopram, but not citalopram or R-citalopram, of the effects of low-dose risperidone: behavioral, biochemical, and electeophysiological evidence. Synapse, 2012, 66, 277–290.

    Article  CAS  PubMed  Google Scholar 

  25. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH et al.: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psycho-pharmacol, 2008, 28, 156–165.

    Article  CAS  PubMed  Google Scholar 

  26. McIntyre A, Gendron A: Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety, 2007, 24, 487–494.

    Article  CAS  PubMed  Google Scholar 

  27. Meltzer HY: The mechanism of action of novel antipsy-chotic drugs. Schizophr Bull, 1991, 17, 263–287.

    Article  CAS  PubMed  Google Scholar 

  28. Millan MJ, Dekeyne A, Gobert A: Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology, 1998, 37, 953–955.

    Article  CAS  PubMed  Google Scholar 

  29. Nakayama K, Sakurai T, Katsu H: Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Brain Res Bull, 2004, 63, 237–231.

    Article  CAS  Google Scholar 

  30. Pessia M, Jiang ZG, North RA, Johnson SW: Actions of 5-hydroxytryptamine on ventral tegmental area neurons of the rat in vitro. Brain Res, 1994, 654, 324–330.

    Article  CAS  PubMed  Google Scholar 

  31. Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, Turkoz I et al.: Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychophar-macology, 2006, 31, 2505–2513.

    Article  CAS  PubMed  Google Scholar 

  32. Reeves H, Batra S, May RS, Zhang R, Dahl DC, Li X: Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry, 2008, 69, 1228–1336.

    Article  CAS  PubMed  Google Scholar 

  33. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci, 2000, 68, 29–39.

    Article  CAS  PubMed  Google Scholar 

  34. Rogóż Z: Effects of co-treatment with mirtazapine and low doses of risperidone on the immobility time in the forced swimming test in mice. Pharmacol Rep, 2010, 62, 1191–1196.

    PubMed  Google Scholar 

  35. Rogóż Z, Kabziński M: Enhancement of the anti-immobility action of antidepressants by risperidone in the forced swimming test in mice. Pharmacol Rep, 2011, 63, 1533–1538.

    Article  PubMed  Google Scholar 

  36. Rogóż Z, Kabziński M, Sadaj W, Rachwalska P, Gądek-Michalska A: Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test. Pharmacol Rep, 2012, 64, 1391–1399.

    Article  PubMed  Google Scholar 

  37. Schatzberg AF, Schildkraut J: Recent studies on norepi-nephrine systems in mood disorders. In: Psychopharma-cology: The Fourth Generation of Progress. Eds. Bloom FE, Kupfer DJ, Raven Press Ltd., New York, 1995, 911–920.

    Google Scholar 

  38. Schilstrőm B, Konradsson-Geuken A, Ivanov V, Gertow J, Feltmann K, Marcus MM, Jardemark K, Svensson TH: Effect of S-citalopram, citalopram, and R-citalopram on the firing patterns of dopamine neurons in the ventral tegmental area, N-methyl-D-aspartate receptor-mediated transmission in the medial prefrontal cortex and cognitive function in the rat. Synapse, 2011, 65, 357–367.

    Article  PubMed  CAS  Google Scholar 

  39. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperi-done compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychophar-macology (Berl), 1996, 124, 57–73.

    Article  CAS  Google Scholar 

  40. Shelton RC: Treatment options for refractory depression. J Clin Psychiatry, 1999, 60, Suppl 4, 57–61.

    PubMed  Google Scholar 

  41. Shelton RC, Papakostas GI: Augmentation of antidepres-sants with atypical antypsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand, 2008, 117, 253–259.

    Article  CAS  PubMed  Google Scholar 

  42. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR et al.: A novel augmentation strategy for treating resistant major depression. Am J Psychiatry, 2001, 158, 131–134.

    Article  CAS  PubMed  Google Scholar 

  43. Shelton RC, Williamson DJ, Corya SA, Sanger TM, Van Campen LE, Case M, Briggs SD, Tollefson GD: Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nor-triptyline resistance. J Clin Psychiatry, 2005, 66, 1289–1297.

    Article  CAS  PubMed  Google Scholar 

  44. Steffens DC, Nelson JC, Eudicone JM, Andersson C, Yang H, Tran QV, Forbes RA et al.: Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. Int J Geriatr Psychiatry, 2011, 26, 564–572.

    Article  PubMed  Google Scholar 

  45. Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, Watson SB, Dubé S: A randomized, double-blind comparison olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry, 2007, 68, 224–236.

    Article  CAS  PubMed  Google Scholar 

  46. Trivedi MH, Thase ME, Osuntokun O, Henley DB, Case M, Watson SB, Campbell GM, Corya SA: An inter-grated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry, 2009, 70, 387–396.

    Article  CAS  PubMed  Google Scholar 

  47. Willner P: Dopaminergic mechanism in depression and mania. In: Psychopharmacology: The Fourth Generation of Progress. Eds. Bloom FE, Kupfer DJ, Raven Press Ltd., New York, 1995, 921–931.

    Google Scholar 

  48. Wright BM, Eiland III EH, Lorenz R: Augmentation with atypical antipsychotics for depression: A review of evidence-based support from the medical literature. Pharmacotherapy, 2013, 33, 344–359.

    Article  CAS  PubMed  Google Scholar 

  49. Zajdel P, Marciniec K, Maślankiewicz A, Grychowska K, Satała G, Duszyńska B, Lenda T et al.: Antidepres-sant and antipsychotic activity of new quinaline- and isoquinaline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT1A/5-HT2A/5-HT7 and dopamine D2/D3 receptors. Eur J Med Chem, 2013, 60, 42–50.

    Article  CAS  PubMed  Google Scholar 

  50. Zhang W, Perry KW, Wong DT, Potts BD, Bao JQ, Tollefson GD, Bymaster FP: Synergistic effect of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology, 2000, 23, 250–262.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Smętna 12, PL 31-343, Poland

    Zofia Rogóż

Authors
  1. Zofia Rogóż
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zofia Rogóż.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rogóż, Z. Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: preclinical and clinical efficacy. Pharmacol. Rep 65, 1535–1544 (2013). https://doi.org/10.1016/S1734-1140(13)71515-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1016/S1734-1140(13)71515-9

Key words

Search

Navigation